Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes.

@article{Morganti2006RandomizedCT,
  title={Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes.},
  author={Alberto Morganti},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2006},
  volume={17 4 Suppl 2},
  pages={
          S141-4
        }
}
  • A. Morganti
  • Published 1 April 2006
  • Medicine
  • Journal of the American Society of Nephrology : JASN
Hard end point studies represent the best available evidence for demonstrating the cardiovascular and renal protection that is achievable with a given treatment in hypertensive patients, yet properly designed end point studies require large cohorts of patients and long follow-up, are expensive, and do not provide any insight on the mechanisms that lead to the clinical manifestations. Studies that are based on the incidence of preclinical alterations, i.e., the surrogate end points, may… 
View on PubMed
jasn.asnjournals.org
5 Citations
Highly Influential Citations
1
Background Citations
3

5 Citations

Citation Type

Citation Type

Modeling hard clinical end-point data in economic analyses
TLDR
Key considerations for cost-effectiveness models incorporating hard end-point data include the frequency and characteristics of the relevant clinical events and how the trial data is reported.
The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.
TLDR
There was no clear and consistent association between intervention-induced LVM change and mortality and evidence for LVM as a valid surrogate end point in CKD is currently lacking.
Pathophysiologic therapeutic targets in hypertension: a cardiological point of view
TLDR
From a pathophysiological point of view, inhibitors of the renin–angiotensin–aldosterone system could be considered as the most appropriate drugs for the treatment of arterial hypertension and its correlates, especially in the high-risk patient.
Changes in surrogate outcomes can be translated into clinical outcomes using a Monte Carlo model.
Microbial nucleic acids pay a Toll in kidney disease.
TLDR
Recent advances in nucleic acids have been summarized and new hypotheses for the pathogenesis of kidney diseases that are triggered by infectious organisms are discussed.

References

SHOWING 1-10 OF 29 REFERENCES
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy
TLDR
Baseline albuminuria is a powerful risk factor for CV events and one-fifth of the difference in favor of losartan on the primary CEP was explained by the greater reduction inalbuminuria onLosartan.
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
TLDR
Albuminuria is the predominant renal risk marker in patients with type 2 diabetic nephropathy on conventional treatment; the higher the albuminuria, the greater the renal risk and the stronger the renal protection.
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
TLDR
In treated hypertensive subjects, occurrence of new diabetes portends a risk for subsequent cardiovascular disease that is not dissimilar from that of previously known diabetes.
Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis.
Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
TLDR
The present findings strongly indicate that the lack of decrease or the increase of left ventricular mass after antihypertensive treatment can be associated with a higher risk for cardiovascular events, which is significantly reduced and almost normalized by complete regression ofleft ventricular hypertrophy.
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
TLDR
The results indicate that any degree of albuminuria is a risk factor for CV events in individuals with or without DM; the risk increases with the ACR, starting well below the microalbuminuria cutoff.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
TLDR
Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive and should be preferred for first-step antihypertensive therapy.
When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk.
TLDR
It is observed that the occurrence of a new onset of diabetes in treated hypertensive patients carried a risk for subsequent cardiovascular disease (CVD) events that was not statistically different from those who already had diabetes and hypertension at the onset of the study.
Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy.
TLDR
Results of this investigation suggest that regression of ECG features of left ventricular hypertrophy confers an improvement in risk for cardiovascular disease, whereas serial worsening imposes increased risk.
Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study
TLDR
Men who received antihypertensive treatment showed a larger increase in blood glucose during a 10 year period than those without such treatment, indicating that both an insulin resistant state and the metabolic impact of β blockers and diuretics increase the risk of myocardial infarction.
...
1
2
3
...